Fei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fei Chen has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Jun Liu
Department of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China
20 shared publications Jun Liu
Department of Otolaryngology–Head and Neck Surgery West China Hospital, Sichuan University Chengdu China
15 shared publications- Zheng Jiang
Department of Otolaryngology–Head and Neck Surgery West China Hospital, Sichuan University Chengdu China
13 shared publications Di Deng
Department of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China
12 shared publicationsZheng Jiang
Department of Otolaryngology‐Head & Neck Surgery West China Hospital Sichuan University Chengdu China
10 shared publicationsHaiyang Wang
Department of Otolaryngology, Head and Neck Surgery West China Hospital, Sichuan University Chengdu China
9 shared publications
Latest Publications
- 27 October 2026
- Published by Wiley in The Laryngoscope
Multidimensional Analysis of Immune Rejection in a Murine HLA ‐Mismatched Laryngeal Transplant Model
Objective: To establish a murine heterotopic laryngeal transplantation (LT) model with a single HLA‐A2 mismatch and to develop a multidimensional framework for dynamic evaluation of immune rejection and graft injury. Methods: Laryngeal grafts from HLA‐A2 transgenic mice were transplanted into C57BL/6 recipients to generate an HLA‐mismatched LT model, with syngeneic C57BL/6 → C57BL/6 transplants as controls. A multidimensional evaluation system was established, integrating physiological monitoring (survival, body weight, graft appearance, neck circumference, computed tomography, and ultrasonography), immunological profiling (histopathology, immunohistochemistry, and flow cytometry), and inflammatory assessments (cytokines and biochemical parameters) from Day 0 to 12 weeks posttransplantation. Results: Compared with syngeneic transplantation, the HLA‐mismatched group showed aggravated immune rejection and graft injury. Progressive graft volume reduction was an early discriminator, detectable at 1 week posttransplantation and correlating with graft surface darkening and ulceration. Immunophenotyping revealed early CD4 + and CD8 + T‐cell infiltration beginning at 1 week, whereas regulatory T cells increased at 3 days before markedly declining. Cytokine profiling showed elevations of MIP‐1β, G‐CSF, and IL‐10 from 4 weeks onward, consistent with immune activation and graft injury. Conclusion: A murine heterotopic LT model with an HLA‐A2 mismatch was established, demonstrating that a single HLA Class I disparity was sufficient to drive progressive immune rejection and graft injury in LT. A panel of biomarkers associated with adverse graft outcomes was observed, providing indicators for monitoring HLA‐driven immune injury. Level of Evidence: N/A.
- 27 October 2026
- Published by Wiley in The Laryngoscope
Multidimensional Analysis of Immune Rejection in a Murine HLA ‐Mismatched Laryngeal Transplant Model
Objective: To establish a murine heterotopic laryngeal transplantation (LT) model with a single HLA‐A2 mismatch and to develop a multidimensional framework for dynamic evaluation of immune rejection and graft injury. Methods: Laryngeal grafts from HLA‐A2 transgenic mice were transplanted into C57BL/6 recipients to generate an HLA‐mismatched LT model, with syngeneic C57BL/6 → C57BL/6 transplants as controls. A multidimensional evaluation system was established, integrating physiological monitoring (survival, body weight, graft appearance, neck circumference, computed tomography, and ultrasonography), immunological profiling (histopathology, immunohistochemistry, and flow cytometry), and inflammatory assessments (cytokines and biochemical parameters) from Day 0 to 12 weeks posttransplantation. Results: Compared with syngeneic transplantation, the HLA‐mismatched group showed aggravated immune rejection and graft injury. Progressive graft volume reduction was an early discriminator, detectable at 1 week posttransplantation and correlating with graft surface darkening and ulceration. Immunophenotyping revealed early CD4 + and CD8 + T‐cell infiltration beginning at 1 week, whereas regulatory T cells increased at 3 days before markedly declining. Cytokine profiling showed elevations of MIP‐1β, G‐CSF, and IL‐10 from 4 weeks onward, consistent with immune activation and graft injury. Conclusion: A murine heterotopic LT model with an HLA‐A2 mismatch was established, demonstrating that a single HLA Class I disparity was sufficient to drive progressive immune rejection and graft injury in LT. A panel of biomarkers associated with adverse graft outcomes was observed, providing indicators for monitoring HLA‐driven immune injury. Level of Evidence: N/A.
- Open Access
- 1 October 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (10) , 297
Dagnostic challenge of thyroid-derived papillary carcinoma along the embryologic thyroid descent pathway: a report of three cases
Background: Thyroid tissue descends from the foramen cecum to the pretracheal neck. Remnants along this pathway may form ectopic thyroid tissue or thyroglossal duct cysts (TGDCs), and rarely develop papillary thyroid carcinoma (PTC). These tumors may mimic benign cystic or cystic-solid lesions, making risk stratification, diagnosis of origin, and surgical planning difficult. Case Description: Three women had thyroid-derived PTC at descent-pathway sites. Case 1 was a 33-year-old woman treated by Sistrunk procedure for presumed TGDC after fine-needle aspiration yielded cystic contents. Final pathology showed TGDC-PTC invading fibrous and skeletal muscle tissue, with BRAF V600E positivity; postoperative tongue-base and pharyngeal edema required emergency tracheotomy. Case 2 was a 29-year-old woman with a tongue-base lesion present before total thyroidectomy and central neck dissection for orthotopic pT1aN0M0 PTC. Transoral excision showed a 17-mm thyroid-derived PTC clinically favored as lingual thyroid PTC, with negative margins and no BRAF V600E or TERT promoter mutation; no local recurrence was seen at 15 months. Case 3 was a 57-year-old woman with an anterior midline hyoid-region lesion in which imaging suggested ectopic thyroid carcinoma or metastatic PTC. Frozen section confirmed thyroid-derived PTC with negative margins, supporting Sistrunk-type local excision and staged surveillance of the orthotopic thyroid; early postoperative ultrasound showed no suspicious cervical lymph node. Conclusions: Tongue-base, hyoid-region, and anterior midline lesions should be assessed together with the orthotopic thyroid and cervical lymph nodes. Histology and immunohistochemistry confirm thyroid follicular-cell origin but may not fully distinguish ectopic thyroid carcinoma, TGDC carcinoma, and metastatic PTC. Management should be guided by tumor size, invasion, margin and nodal status, orthotopic thyroid findings, molecular features, airway risk, and follow-up reliability.
- 1 October 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (10) , 297
Open AccessDagnostic challenge of thyroid-derived papillary carcinoma along the embryologic thyroid descent pathway: a report of three cases
Background: Thyroid tissue descends from the foramen cecum to the pretracheal neck. Remnants along this pathway may form ectopic thyroid tissue or thyroglossal duct cysts (TGDCs), and rarely develop papillary thyroid carcinoma (PTC). These tumors may mimic benign cystic or cystic-solid lesions, making risk stratification, diagnosis of origin, and surgical planning difficult. Case Description: Three women had thyroid-derived PTC at descent-pathway sites. Case 1 was a 33-year-old woman treated by Sistrunk procedure for presumed TGDC after fine-needle aspiration yielded cystic contents. Final pathology showed TGDC-PTC invading fibrous and skeletal muscle tissue, with BRAF V600E positivity; postoperative tongue-base and pharyngeal edema required emergency tracheotomy. Case 2 was a 29-year-old woman with a tongue-base lesion present before total thyroidectomy and central neck dissection for orthotopic pT1aN0M0 PTC. Transoral excision showed a 17-mm thyroid-derived PTC clinically favored as lingual thyroid PTC, with negative margins and no BRAF V600E or TERT promoter mutation; no local recurrence was seen at 15 months. Case 3 was a 57-year-old woman with an anterior midline hyoid-region lesion in which imaging suggested ectopic thyroid carcinoma or metastatic PTC. Frozen section confirmed thyroid-derived PTC with negative margins, supporting Sistrunk-type local excision and staged surveillance of the orthotopic thyroid; early postoperative ultrasound showed no suspicious cervical lymph node. Conclusions: Tongue-base, hyoid-region, and anterior midline lesions should be assessed together with the orthotopic thyroid and cervical lymph nodes. Histology and immunohistochemistry confirm thyroid follicular-cell origin but may not fully distinguish ectopic thyroid carcinoma, TGDC carcinoma, and metastatic PTC. Management should be guided by tumor size, invasion, margin and nodal status, orthotopic thyroid findings, molecular features, airway risk, and follow-up reliability.
- Open Access
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e014100
Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study
Background: While immune checkpoint inhibitor-based neoadjuvant therapy shows promise in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the optimal regimen has yet to be established. We report, for the first time, a neoadjuvant treatment that combines chemotherapy with dual blockade of the programmed cell death protein 1 and epidermal growth factor receptor pathways in LA-HNSCC. Methods: In this single-arm phase 2 trial ( NCT05516589 ) conducted at a single academic center, patients with LA-HNSCC were enrolled and received two cycles of tislelizumab and TP chemotherapy (nab-paclitaxel and cisplatin), administered on day 1 of each 3-week cycle, along with afatinib during the interval between chemoimmunotherapy cycles, followed by surgical resection. The primary endpoint was the complete pathologic response (pCR) rate. Secondary endpoints included the major pathologic response (MPR) rate, objective response rate (ORR), event-free survival, overall survival (OS), and safety. Results: A total of 40 patients were enrolled and received neoadjuvant treatment, 32 of whom proceeded to surgical resection; among these patients, the pCR rate was 40.6% (95% CI 23.7% to 59.4%). The ORR was 82.5% (95% CI 67.2% to 92.7%). The 1-year OS rate was 97.3% (95% CI 92.2% to 100%). The most common treatment-related adverse event (TRAE) of grade 3−4 was lymphopenia (5/40, 12.5%). No grade 5 TRAEs leading to death occurred, and no treatment-related surgical delays were observed. In the prespecified exploratory biomarker analysis, increased cytotoxic T lymphocytes and B cells in the tumor immune microenvironment may be associated with pCR/MPR. Neoadjuvant treatment induced a significant increase in the proportion of peripheral CD8+T cells, along with a reduction in B cells. Conclusions: We report, for the first time, the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with afatinib in patients with LA-HNSCC. Neoadjuvant treatment potentially induced an immune-enhanced tumor microenvironment. Further evaluation in large-scale clinical trials with longer follow-up periods is needed. Trial registration number: NCT05516589 .
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e014100
Open AccessNeoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study
Background: While immune checkpoint inhibitor-based neoadjuvant therapy shows promise in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the optimal regimen has yet to be established. We report, for the first time, a neoadjuvant treatment that combines chemotherapy with dual blockade of the programmed cell death protein 1 and epidermal growth factor receptor pathways in LA-HNSCC. Methods: In this single-arm phase 2 trial ( NCT05516589 ) conducted at a single academic center, patients with LA-HNSCC were enrolled and received two cycles of tislelizumab and TP chemotherapy (nab-paclitaxel and cisplatin), administered on day 1 of each 3-week cycle, along with afatinib during the interval between chemoimmunotherapy cycles, followed by surgical resection. The primary endpoint was the complete pathologic response (pCR) rate. Secondary endpoints included the major pathologic response (MPR) rate, objective response rate (ORR), event-free survival, overall survival (OS), and safety. Results: A total of 40 patients were enrolled and received neoadjuvant treatment, 32 of whom proceeded to surgical resection; among these patients, the pCR rate was 40.6% (95% CI 23.7% to 59.4%). The ORR was 82.5% (95% CI 67.2% to 92.7%). The 1-year OS rate was 97.3% (95% CI 92.2% to 100%). The most common treatment-related adverse event (TRAE) of grade 3−4 was lymphopenia (5/40, 12.5%). No grade 5 TRAEs leading to death occurred, and no treatment-related surgical delays were observed. In the prespecified exploratory biomarker analysis, increased cytotoxic T lymphocytes and B cells in the tumor immune microenvironment may be associated with pCR/MPR. Neoadjuvant treatment induced a significant increase in the proportion of peripheral CD8+T cells, along with a reduction in B cells. Conclusions: We report, for the first time, the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with afatinib in patients with LA-HNSCC. Neoadjuvant treatment potentially induced an immune-enhanced tumor microenvironment. Further evaluation in large-scale clinical trials with longer follow-up periods is needed. Trial registration number: NCT05516589 .
- 3 September 2026
- Published by Wiley in The Laryngoscope
Two‐Stage Tracheal Repair for Well‐Differentiated Thyroid Carcinoma With Tracheal Invasion
Objective: To evaluate a two‐stage tracheal reconstruction strategy for repairing extensive tracheal defects in well‐differentiated thyroid carcinoma (WDTC) with tracheal invasion. Methods: Seventy‐four patients underwent tumor resection and tracheal excision, followed by staged reconstruction using a free posterior tibial flap ( n = 28), pedicled thoracoacromial flap ( n = 36), or pedicled supraclavicular flap ( n = 10). Functional recovery, decannulation, complications, and survival were analyzed. Results: Demographic characteristics were comparable across groups. Tracheal defects were significantly larger in the free posterior tibial artery perforator flap group (9.14 ± 1.57 rings) versus the pedicled thoracoacromial (5.89 ± 2.59 rings) and supraclavicular (6.30 ± 1.49 rings) flap groups. The overall endotracheal tube removal rate was 95.9%, with no intergroup differences ( p = 0.533). Functional recovery (swallowing, speech, and respiration) was comparable among groups. The 3‐year survival rate was 78.4%, with no significant differences across groups ( p = 0.633). Conclusions: Two‐stage tracheal reconstruction is a safe and effective approach for long‐segment tracheal defects in WDTC patients, offering satisfactory functional recovery. Further studies with larger cohorts and longer follow‐up are warranted to confirm long‐term efficacy. Level of Evidence: 4.
- 3 September 2026
- Published by Wiley in The Laryngoscope
Two‐Stage Tracheal Repair for Well‐Differentiated Thyroid Carcinoma With Tracheal Invasion
Objective: To evaluate a two‐stage tracheal reconstruction strategy for repairing extensive tracheal defects in well‐differentiated thyroid carcinoma (WDTC) with tracheal invasion. Methods: Seventy‐four patients underwent tumor resection and tracheal excision, followed by staged reconstruction using a free posterior tibial flap ( n = 28), pedicled thoracoacromial flap ( n = 36), or pedicled supraclavicular flap ( n = 10). Functional recovery, decannulation, complications, and survival were analyzed. Results: Demographic characteristics were comparable across groups. Tracheal defects were significantly larger in the free posterior tibial artery perforator flap group (9.14 ± 1.57 rings) versus the pedicled thoracoacromial (5.89 ± 2.59 rings) and supraclavicular (6.30 ± 1.49 rings) flap groups. The overall endotracheal tube removal rate was 95.9%, with no intergroup differences ( p = 0.533). Functional recovery (swallowing, speech, and respiration) was comparable among groups. The 3‐year survival rate was 78.4%, with no significant differences across groups ( p = 0.633). Conclusions: Two‐stage tracheal reconstruction is a safe and effective approach for long‐segment tracheal defects in WDTC patients, offering satisfactory functional recovery. Further studies with larger cohorts and longer follow‐up are warranted to confirm long‐term efficacy. Level of Evidence: 4.
- Open Access
Laryngeal Transplantation in Cancer Patients: Evaluation of Surgical Outcomes and Functional Recovery
Laryngeal transplantation offers a promising avenue for functional restoration following total laryngectomy, yet concerns regarding cancer recurrence and perioperative challenges persist. This pilot study evaluates the preliminary outcomes of a refined surgical technique and postoperative follow‐up protocol specifically for cancer patients. Between 2023 and 2024, four patients underwent laryngeal transplantation at West China Hospital, with immunosuppressive therapy, microbial prophylaxis, and postoperative rehabilitation. Over a follow‐up period ranging from 10 to 26 months, outcomes were heterogeneous. Two recipients (T4 laryngeal squamous cell carcinoma) achieved excellent functional recovery in swallowing and phonation with sustained rejection‐free survival for 20 and 23 months and disease‐free survival for 20 and 26 months, respectively, though both remained tracheostoma dependent. One of these survivors is currently undergoing treatment for graft rejection after unilateral cessation of immunosuppressants. The remaining two patients succumbed to severe pneumonia with sepsis and tumor recurrence at 10 and 11 months posttransplant. Functional assessments in surviving cases indicated progressive nerve regeneration, with optimal voice and swallowing outcomes achieved approximately 6–8 months postsurgery. Ultimately, these findings demonstrate the technical feasibility of laryngeal transplantation in a pilot cohort of cancer patients, providing critical data for future protocol refinement.
Open AccessLaryngeal Transplantation in Cancer Patients: Evaluation of Surgical Outcomes and Functional Recovery
Laryngeal transplantation offers a promising avenue for functional restoration following total laryngectomy, yet concerns regarding cancer recurrence and perioperative challenges persist. This pilot study evaluates the preliminary outcomes of a refined surgical technique and postoperative follow‐up protocol specifically for cancer patients. Between 2023 and 2024, four patients underwent laryngeal transplantation at West China Hospital, with immunosuppressive therapy, microbial prophylaxis, and postoperative rehabilitation. Over a follow‐up period ranging from 10 to 26 months, outcomes were heterogeneous. Two recipients (T4 laryngeal squamous cell carcinoma) achieved excellent functional recovery in swallowing and phonation with sustained rejection‐free survival for 20 and 23 months and disease‐free survival for 20 and 26 months, respectively, though both remained tracheostoma dependent. One of these survivors is currently undergoing treatment for graft rejection after unilateral cessation of immunosuppressants. The remaining two patients succumbed to severe pneumonia with sepsis and tumor recurrence at 10 and 11 months posttransplant. Functional assessments in surviving cases indicated progressive nerve regeneration, with optimal voice and swallowing outcomes achieved approximately 6–8 months postsurgery. Ultimately, these findings demonstrate the technical feasibility of laryngeal transplantation in a pilot cohort of cancer patients, providing critical data for future protocol refinement.
- 26 March 2026
- Published by Wiley in International Journal of Language & Communication Disorders
- Vol. 61 (3) , e70228
Functional Voice Restoration After Laryngeal Transplantation: A Multidisciplinary Protocol and Longitudinal Outcomes
Introduction: Laryngeal transplantation offers the potential for patients to regain vocal function, yet standardised voice rehabilitation protocols are lacking. We share the experience of our team in the regular follow‐up of voice function evaluation and address this gap by establishing a multidisciplinary pathway for functional recovery. Methods: Four male transplant recipients (3 laryngeal cancers, 1 hypopharyngeal cancer) underwent protocolized assessments at 1/3/6/8 months post‐op: subjective assessment (GRBAS scale) and objective evaluation (multiparametric acoustic analysis and electronic laryngoscopy). Personalized rehabilitation was delivered weekly by a licensed speech therapist. Protocol evolution occurred: Patients 1–2 received conventional training; Patients 3–4 received intensive neuromuscular reinnervation strategies. Results: The voice of the four patients showed a gradual decrease in the degree of hoarseness, a gradual alleviation of breathiness, and a gradual decrease in asthenia score, with the overall condition improving. The MPT was about 1.8 s at 1 month after surgery which kept increasing in all patients. The 3rd patient, who performed the best among the 4 patients, had an MPT of more than 10 s at 8 months after surgery. Laryngeal mucosa sensory function was gradually established in patients starting 3 months after operation, and compensatory vibration of ventricular band appeared at 8 months after operation with the assistance of voice training. Conclusions: This study anchored to neuromuscular reinnervation milestones demonstrates that standardised evaluations coupled with individualized training progressively restore vocal function. Our protocolized framework guides evidence‐based rehabilitation for institutions pursuing laryngeal transplantation WHAT THIS PAPER ADDS: What is already known on this subject Laryngeal transplantation surgically restores laryngeal anatomy but faces functional recovery challenges due to delayed neuromuscular reinnervation. Existing literature focuses predominantly on immunosuppression and graft viability, with sparse evidence guiding postoperative voice rehabilitation. Standardised protocols for phonatory recovery—routine in other neurogenic voice disorders (e.g., vocal fold paralysis)—are absent. Fewer than 20 human cases have been reported globally, and only two publications detail voice outcomes. Consequently, rehabilitation strategies remain ad hoc, lacking consensus on intervention timing, exercise biomarkers, or psychological support frameworks. What this study adds to existing knowledge This study establishes the first protocolized voice rehabilitation framework for laryngeal transplantation, anchored to neuromuscular milestones: Pharyngeal reflex recovery (3 months) signalling sensory reinnervation; Ventricular band compensation (8 months) indicating motor adaptation. We demonstrate that early, structured rehabilitation (initiated at 1 month) enables significant voice restoration (MPT: 1.8 s → >10 s). Critically, we identify modular design principles accommodating clinical interruptions (e.g., ICU admissions) without compromising core outcomes. We anticipate these findings will guide evidence‐based rehabilitation for institutions pursuing laryngeal transplantation and inform standardised pathways for complex laryngologic rehabilitation. What are the potential or actual clinical implications of this work? Rehabilitation Standardization : Provides evidence‐based timelines (1/3/6/8‐month assessments) and neuromuscular biomarkers to guide intervention intensity. Broad Applicability : The protocol shows cross‐utility for bilateral vocal fold paralysis and post‐traumatic neurogenic dysphonia, leveraging shared reinnervation mechanisms. Contingency Management : Modular training design maintains efficacy despite clinical interruptions (e.g., 40% cohort ICU/oncology transfers). Technology Integration : Validates objective metrics (MPT, mucosal wave symmetry) as targets for future AI‐assisted biofeedback tools. Clinicians should prioritise early sensorimotor retraining (<3 months) while monitoring compensatory strategies (ventricular vibration) as functional proxies.
- 26 March 2026
- Published by Wiley in International Journal of Language & Communication Disorders
- Vol. 61 (3) , e70228
Functional Voice Restoration After Laryngeal Transplantation: A Multidisciplinary Protocol and Longitudinal Outcomes
Introduction: Laryngeal transplantation offers the potential for patients to regain vocal function, yet standardised voice rehabilitation protocols are lacking. We share the experience of our team in the regular follow‐up of voice function evaluation and address this gap by establishing a multidisciplinary pathway for functional recovery. Methods: Four male transplant recipients (3 laryngeal cancers, 1 hypopharyngeal cancer) underwent protocolized assessments at 1/3/6/8 months post‐op: subjective assessment (GRBAS scale) and objective evaluation (multiparametric acoustic analysis and electronic laryngoscopy). Personalized rehabilitation was delivered weekly by a licensed speech therapist. Protocol evolution occurred: Patients 1–2 received conventional training; Patients 3–4 received intensive neuromuscular reinnervation strategies. Results: The voice of the four patients showed a gradual decrease in the degree of hoarseness, a gradual alleviation of breathiness, and a gradual decrease in asthenia score, with the overall condition improving. The MPT was about 1.8 s at 1 month after surgery which kept increasing in all patients. The 3rd patient, who performed the best among the 4 patients, had an MPT of more than 10 s at 8 months after surgery. Laryngeal mucosa sensory function was gradually established in patients starting 3 months after operation, and compensatory vibration of ventricular band appeared at 8 months after operation with the assistance of voice training. Conclusions: This study anchored to neuromuscular reinnervation milestones demonstrates that standardised evaluations coupled with individualized training progressively restore vocal function. Our protocolized framework guides evidence‐based rehabilitation for institutions pursuing laryngeal transplantation WHAT THIS PAPER ADDS: What is already known on this subject Laryngeal transplantation surgically restores laryngeal anatomy but faces functional recovery challenges due to delayed neuromuscular reinnervation. Existing literature focuses predominantly on immunosuppression and graft viability, with sparse evidence guiding postoperative voice rehabilitation. Standardised protocols for phonatory recovery—routine in other neurogenic voice disorders (e.g., vocal fold paralysis)—are absent. Fewer than 20 human cases have been reported globally, and only two publications detail voice outcomes. Consequently, rehabilitation strategies remain ad hoc, lacking consensus on intervention timing, exercise biomarkers, or psychological support frameworks. What this study adds to existing knowledge This study establishes the first protocolized voice rehabilitation framework for laryngeal transplantation, anchored to neuromuscular milestones: Pharyngeal reflex recovery (3 months) signalling sensory reinnervation; Ventricular band compensation (8 months) indicating motor adaptation. We demonstrate that early, structured rehabilitation (initiated at 1 month) enables significant voice restoration (MPT: 1.8 s → >10 s). Critically, we identify modular design principles accommodating clinical interruptions (e.g., ICU admissions) without compromising core outcomes. We anticipate these findings will guide evidence‐based rehabilitation for institutions pursuing laryngeal transplantation and inform standardised pathways for complex laryngologic rehabilitation. What are the potential or actual clinical implications of this work? Rehabilitation Standardization : Provides evidence‐based timelines (1/3/6/8‐month assessments) and neuromuscular biomarkers to guide intervention intensity. Broad Applicability : The protocol shows cross‐utility for bilateral vocal fold paralysis and post‐traumatic neurogenic dysphonia, leveraging shared reinnervation mechanisms. Contingency Management : Modular training design maintains efficacy despite clinical interruptions (e.g., 40% cohort ICU/oncology transfers). Technology Integration : Validates objective metrics (MPT, mucosal wave symmetry) as targets for future AI‐assisted biofeedback tools. Clinicians should prioritise early sensorimotor retraining (<3 months) while monitoring compensatory strategies (ventricular vibration) as functional proxies.
- 7 February 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (3) , 1870-1873
Novel Butterfly-Shaped Bilateral Deltopectoral Flap Reconstruction for Near-Circumferential Trachea Defects
- 7 February 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (3) , 1870-1873
Novel Butterfly-Shaped Bilateral Deltopectoral Flap Reconstruction for Near-Circumferential Trachea Defects
- Open Access
- 21 January 2026
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 55
Surgical Margin Reduction After Immunotargeted Neoadjuvant Therapy in Locally Advanced Hypopharyngeal Carcinoma: A Preliminary Margin Results from neoCHANCE-1 Trial
Importance: Hypopharyngeal squamous cell carcinoma (HPSCC) is an aggressive cancer with poor outcomes. Neoadjuvant therapy (NAT) may allow organ preservation, but determining safe surgical margins after NAT is a critical challenge. Objective: To evaluate the safety of reduced surgical margins after neoadjuvant tislelizumab and afatinib in locally advanced HPSCC by comparing pathological margins to an upfront surgery control group. Design: Prospective, single-center pilot cohort study. Setting: Tertiary referral center in Western China. Participants: Forty-one patients with locally advanced HPSCC; 32 received NAT (treatment group), and 9 served as an upfront surgery control group. Intervention or Exposures: Treatment group: 2 cycles of neoadjuvant tislelizumab plus 6 weeks of afatinib. Control group: upfront surgery. Both groups underwent resection with a 1.5 cm naked-eye surgical margin. Main Outcome Measures: Primary outcomes were minimal peripheral surgical margin (MPSM) and minimal deep surgical margin (MDSM). Secondary outcomes included radiological (RECIST v1.1) and pathological tumor response. Results: The NAT group had a 20/32 (62.5%) radiological objective response rate and a 16/32 (50.0%) major pathological response rate [including 9/32 (28.13%) pathological complete response]. The mean MPSM was significantly greater in the treatment group versus control [3.38 mm vs 1.71 mm; 95% Confidence interval (CI): 0.10-3.24; P = .038]. The mean MDSM was also significantly greater in the treatment group versus control (2.09 mm vs 1.04 mm; 95% CI: 0.12-1.97; P = .029). Conclusions: Combined immune-targeted NAT effectively downstages HPSCC. The significantly larger pathological margins observed support that reducing clinical surgical margins after this regimen is generally safe. Relevance: This NAT regimen may allow for less extensive resections, facilitating laryngeal preservation and improving quality of life without compromising oncologic safety. Larger validation studies are needed.
- 21 January 2026
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 55
Open AccessSurgical Margin Reduction After Immunotargeted Neoadjuvant Therapy in Locally Advanced Hypopharyngeal Carcinoma: A Preliminary Margin Results from neoCHANCE-1 Trial
Importance: Hypopharyngeal squamous cell carcinoma (HPSCC) is an aggressive cancer with poor outcomes. Neoadjuvant therapy (NAT) may allow organ preservation, but determining safe surgical margins after NAT is a critical challenge. Objective: To evaluate the safety of reduced surgical margins after neoadjuvant tislelizumab and afatinib in locally advanced HPSCC by comparing pathological margins to an upfront surgery control group. Design: Prospective, single-center pilot cohort study. Setting: Tertiary referral center in Western China. Participants: Forty-one patients with locally advanced HPSCC; 32 received NAT (treatment group), and 9 served as an upfront surgery control group. Intervention or Exposures: Treatment group: 2 cycles of neoadjuvant tislelizumab plus 6 weeks of afatinib. Control group: upfront surgery. Both groups underwent resection with a 1.5 cm naked-eye surgical margin. Main Outcome Measures: Primary outcomes were minimal peripheral surgical margin (MPSM) and minimal deep surgical margin (MDSM). Secondary outcomes included radiological (RECIST v1.1) and pathological tumor response. Results: The NAT group had a 20/32 (62.5%) radiological objective response rate and a 16/32 (50.0%) major pathological response rate [including 9/32 (28.13%) pathological complete response]. The mean MPSM was significantly greater in the treatment group versus control [3.38 mm vs 1.71 mm; 95% Confidence interval (CI): 0.10-3.24; P = .038]. The mean MDSM was also significantly greater in the treatment group versus control (2.09 mm vs 1.04 mm; 95% CI: 0.12-1.97; P = .029). Conclusions: Combined immune-targeted NAT effectively downstages HPSCC. The significantly larger pathological margins observed support that reducing clinical surgical margins after this regimen is generally safe. Relevance: This NAT regimen may allow for less extensive resections, facilitating laryngeal preservation and improving quality of life without compromising oncologic safety. Larger validation studies are needed.
- Open Access
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Immunological dynamics in orthotopic compared with subcutaneous murine models of HPV-positive oropharyngeal cancer
The necessity of reliable preclinical models for evaluating the efficacy of novel therapeutic strategies is imperative. Nevertheless, the degree to which tumor-bearing murine models represent the immunological characteristics of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has largely been unexplored. By utilizing single-cell RNA sequencing technology, our research elucidated that subcutaneous (SC) murine models more accurately reflect the early immunogenic phase of human HPV-positive OPSCC, marked by a stage-dependent increase in effector T-cell infiltration. By contrast, orthotopic (base of tongue, BOT) tumors exhibited a progressive decline of cytotoxic T cells and accumulation of myeloid-derived suppressive cells, paralleling the immune decrease observed in advanced, immune-excluded human tumors. Additionally, our drug responsiveness analysis indicated that early-stage BOT models more accurately replicate the response to PDCD1 blockade, whereas late-stage SC models more accurately mirror the response to CTLA4 blockade akin to human samples. Our findings provide pivotal insights into the suitability of murine models for the preclinical assessment of immunotherapies in HPV-positive OPSCC.
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Open AccessImmunological dynamics in orthotopic compared with subcutaneous murine models of HPV-positive oropharyngeal cancer
The necessity of reliable preclinical models for evaluating the efficacy of novel therapeutic strategies is imperative. Nevertheless, the degree to which tumor-bearing murine models represent the immunological characteristics of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has largely been unexplored. By utilizing single-cell RNA sequencing technology, our research elucidated that subcutaneous (SC) murine models more accurately reflect the early immunogenic phase of human HPV-positive OPSCC, marked by a stage-dependent increase in effector T-cell infiltration. By contrast, orthotopic (base of tongue, BOT) tumors exhibited a progressive decline of cytotoxic T cells and accumulation of myeloid-derived suppressive cells, paralleling the immune decrease observed in advanced, immune-excluded human tumors. Additionally, our drug responsiveness analysis indicated that early-stage BOT models more accurately replicate the response to PDCD1 blockade, whereas late-stage SC models more accurately mirror the response to CTLA4 blockade akin to human samples. Our findings provide pivotal insights into the suitability of murine models for the preclinical assessment of immunotherapies in HPV-positive OPSCC.
- Open Access
- 26 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (33)
Recurrent hemoptysis after laryngectomy-acquired hemophilia induced by laryngeal cancer surgery and chemoradiotherapy: A case report
BACKGROUND Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by autoantibodies against coagulation factor VIII (FVIII), leading to spontaneous bleeding in patients without a personal or family history of bleeding disorders. While AHA has been reported in association with various cancers, this case represents, to our knowledge, the first reported instance of AHA following head and neck cancer surgery and subsequent chemoradiotherapy. CASE SUMMARY We present the case of a 65-year-old male with a history of hypopharyngeal squamous cell carcinoma (T4bN2cM0, AJCC 8th edition) who developed AHA after extensive surgical resection and chemoradiotherapy. He presented with recurrent hemoptysis and ecchymosis. Coagulation studies showed isolated prolonged activated partial thromboplastin time of 83.8 seconds that did not correct with mixing studies. FVIII activity was < 1%, and a Bethesda assay confirmed FVIII inhibitors with a titer of 18.4 Bethesda units. Hemostasis was initially achieved with tranexamic acid and batroxobin. Immunosuppression with prednisone and cyclophosphamide was started; due to gastrointestinal bleeding, rituximab was added. Treatment was later transitioned to azathioprine with prednisone, followed by tapering. FVIII activity recovered to 188.2%, and the patient remained in remission over six years without AHA or malignancy recurrence. CONCLUSION This case underscores vigilance for AHA after head and neck cancer therapy to enable prompt treatment.
- 26 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (33)
Open AccessRecurrent hemoptysis after laryngectomy-acquired hemophilia induced by laryngeal cancer surgery and chemoradiotherapy: A case report
BACKGROUND Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by autoantibodies against coagulation factor VIII (FVIII), leading to spontaneous bleeding in patients without a personal or family history of bleeding disorders. While AHA has been reported in association with various cancers, this case represents, to our knowledge, the first reported instance of AHA following head and neck cancer surgery and subsequent chemoradiotherapy. CASE SUMMARY We present the case of a 65-year-old male with a history of hypopharyngeal squamous cell carcinoma (T4bN2cM0, AJCC 8th edition) who developed AHA after extensive surgical resection and chemoradiotherapy. He presented with recurrent hemoptysis and ecchymosis. Coagulation studies showed isolated prolonged activated partial thromboplastin time of 83.8 seconds that did not correct with mixing studies. FVIII activity was < 1%, and a Bethesda assay confirmed FVIII inhibitors with a titer of 18.4 Bethesda units. Hemostasis was initially achieved with tranexamic acid and batroxobin. Immunosuppression with prednisone and cyclophosphamide was started; due to gastrointestinal bleeding, rituximab was added. Treatment was later transitioned to azathioprine with prednisone, followed by tapering. FVIII activity recovered to 188.2%, and the patient remained in remission over six years without AHA or malignancy recurrence. CONCLUSION This case underscores vigilance for AHA after head and neck cancer therapy to enable prompt treatment.